Sareum
www.sareum.co.ukSymbol: SAR.L
Currently trading at: 0.138p DOWN 0.031
Sareum Holdings plc is an experienced and specialist Structure-based Drug Discovery company. It accelerates and improves the productivity of both its in-house and partners' discovery research using proprietary approaches.
Sareum is developing a robust pipeline of novel cancer drug candidates for partnering with pharmaceutical companies. It generates revenues to support this pipeline through the provision of specialist discovery research services.
Sareum delivers results through the entire drug discovery value chain, from gene through to valuable preclinical candidate. It carries out complete structure-based discovery programmes for creating novel pre-clinical candidates as well as specific tailored projects to resolve clients' issues in gene to structure, structure to lead, and/or lead to candidate activities.
Sareum creates novel IP and highly valuable clinical candidates for clients across a range of therapeutic areas.
Sareum was founded in August 2003 by Dr Tim Mitchell, Dr David Williams and Dr John Reader as a spin out from Millennium Pharmaceuticals' Structure-Based Discovery Department. Following an initial private investment, the company was successfully admitted to the Alternative Investment Market of the London Stock Exchange in October 2004.
Staff
Contact details
Cambridge
CB2 4EE
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
